Last reviewed · How we verify

Triamcinolone Acetonide/5-fluorouracil mixture — Competitive Intelligence Brief

Triamcinolone Acetonide/5-fluorouracil mixture (Triamcinolone Acetonide/5-fluorouracil mixture) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid/antimetabolite. Area: Oncology.

phase 3 Corticosteroid/antimetabolite Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Triamcinolone Acetonide/5-fluorouracil mixture (Triamcinolone Acetonide/5-fluorouracil mixture) — University of Washington. Triamcinolone Acetonide is a corticosteroid that reduces inflammation, while 5-fluorouracil is an antimetabolite that interferes with DNA synthesis, making cancer cells more susceptible to death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Triamcinolone Acetonide/5-fluorouracil mixture TARGET Triamcinolone Acetonide/5-fluorouracil mixture University of Washington phase 3 Corticosteroid/antimetabolite

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid/antimetabolite class)

  1. University of Washington · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Triamcinolone Acetonide/5-fluorouracil mixture — Competitive Intelligence Brief. https://druglandscape.com/ci/triamcinolone-acetonide-5-fluorouracil-mixture. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: